Legal entity
Every one of those 2 sits in a single category, regulation. America First Policy Institute is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Across a 163-day span, the pace is roughly 0.1 stories per week.
Last mentioned: 4d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, regulation. America First Policy Institute is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Across a 163-day span, the pace is roughly 0.1 stories per week. Source depth averages 2 original sources per story, versus 3.3 across the same-window beat baseline. The 6.5 average consequence score is above the beat benchmark of 6.3 in the same window. Marty Makary appears in 2 tracked Legal stories published from March 10, 2026 through August 19, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 1550 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Marty Makary. Shared-story counts are live from our verified record — not editorial picks.
Trump announces Overton nomination
Trump posts the nomination on social media, calling Overton a ROCKSTAR and quoting HHS Secretary Kennedy: Heidi is ALWAYS RIGHT.
Administration still interviewing FDA candidates
A senior administration official says the search remains open the day before the announcement; Brad Wenstrup and Kyle Diamantas have already declined.
Trump signs childhood-vaccination executive order
Overton stands at Trump's side and urges blue states to adopt the administration's gold standard recommendations, which many physicians say lack scientific support.
Marty Makary resigns as FDA commissioner
Makary steps down after clashes with the White House, creating the vacancy Overton would fill.
Document Request
Expected date for formal requests for internal FDA communications regarding DMD drug applications.
Investigation Announced
Sen. Ron Johnson publicly declares a formal inquiry into the FDA's rare disease drug approval process.
Commissioner Consultation
Johnson speaks with FDA Commissioner Marty Makary to discuss specific drug rejections and agency policy.
Trump's nomination of Heidi Overton to lead the FDA sets up a high-stakes Senate confirmation and a new era of administrative rulemaking on vaccines and food safety. Regulatory lawyers are watching the precedent set by the narrow CDC confirmation of Erica Schwartz and the legal vulnerabilities in the administration's childhood-vaccination executive order.
Senator Ron Johnson (R-Wis.) has initiated a formal investigation into the FDA’s regulatory processes regarding the rejection of biologic therapies for Duchenne muscular dystrophy and other rare diseases. The probe follows high-level discussions with FDA Commissioner Marty Makary and focuses on whether the agency's evidentiary standards are too restrictive for life-threatening conditions.
Source: MedPage Today · STAT News
Marty Makary is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
